晨光生物(300138.SZ):擬投2608.24萬美元在贊比亞投建“贊比亞天然色素項目”
格隆匯10月8日丨晨光生物(300138.SZ)公佈,公司第四屆董事會第三十四次會議審議通過了《關於投建贊比亞天然色素項目的議案》,公司計劃投資2608.24萬美元在贊比亞投建“贊比亞天然色素項目”,主要從事萬壽菊、辣椒、甜葉菊、水飛薊等農作物種植,並逐步加工、銷售等。公司將新設子公司具體負責該項目的籌建及運營。
項目建設規模:項目區計劃總面積4000公頃,其中已經配套噴灌機灌溉種植面積1270公頃,雨季可種植園外面積341公頃,後續可開發土地面積2269公頃。本着“循序漸進,持續發展”的原則,採用“分期種植,滾動經營”的運營模式,在確保生態功能穩定的前提下,對區內綜合資源進行利用。
項目購買農場後,先期將1611公頃的耕地用於萬壽菊種植,預計年產64800到86400噸萬壽菊花,可加工成749.4噸葉黃素浸膏。配套建設日產60噸菊花顆粒生產線和日投料量200噸顆粒的萃取生產線,用於自產萬壽菊花的深加工,葉黃素浸膏出口到國內,在晨光生物科技集團總部生產基地再進行深加工或直接對外銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.